US4526988A
(en)
*
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
DE3587500T2
(de)
*
|
1984-12-04 |
1993-12-16 |
Lilly Co Eli |
Tumorbehandlung bei Säugetieren.
|
ZA859008B
(en)
*
|
1984-12-04 |
1987-07-29 |
Lilly Co Eli |
The treatment of tumors in mammals
|
US4681873A
(en)
*
|
1985-07-29 |
1987-07-21 |
Warner-Lambert Company |
4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
|
CA1295998C
(en)
*
|
1985-07-29 |
1992-02-18 |
Sai P. Sunkara |
Nucleosides and their use as antineoplastic agents
|
US4814438A
(en)
*
|
1986-12-24 |
1989-03-21 |
Eli Lilly And Company |
Immunoglobulin conjugates of 2',2'-difluronucleosides
|
RU1787160C
(ru)
*
|
1986-12-24 |
1993-01-07 |
Эли Лилли Энд Компани |
Способ получени иммуноглобулинового конъюгата
|
US4994558A
(en)
*
|
1986-12-24 |
1991-02-19 |
Eli Lilly And Company |
Immunoglobulin conjugates
|
EP0277599A3
(en)
*
|
1987-01-30 |
1990-05-09 |
Asahi Glass Company Ltd. |
Fluorine containing cyclopentane derivatives and processes for their production
|
CA1340645C
(en)
*
|
1987-04-17 |
1999-07-13 |
Victor E. Marquez |
Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus
|
US4965374A
(en)
*
|
1987-08-28 |
1990-10-23 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
ATE179713T1
(de)
*
|
1987-08-28 |
1999-05-15 |
Lilly Co Eli |
Verfahren zur selektiven isolierung von beta-2'- desoxy-2'2'-difluorocytidin oder seiner salze
|
US5223608A
(en)
*
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4914028A
(en)
*
|
1988-02-10 |
1990-04-03 |
Eli Lilly And Company |
Method of preparing beta-2',2'-difluoronucleosides
|
ZA891076B
(en)
*
|
1988-02-16 |
1990-10-31 |
Lilly Co Eli |
2',3'-dideoxy-2',2'-difluoronucleosides
|
US4983724A
(en)
*
|
1988-02-16 |
1991-01-08 |
Eli Lilly And Company |
Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
|
US5644043A
(en)
*
|
1988-02-16 |
1997-07-01 |
Eli Lilly And Company |
2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
|
CA1339964C
(en)
*
|
1988-03-16 |
1998-07-21 |
Dennis A. Carson |
Substituted adenine derivatives useful as therapeutic agents
|
US5057301A
(en)
*
|
1988-04-06 |
1991-10-15 |
Neorx Corporation |
Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
|
JPH0232093A
(ja)
*
|
1988-06-08 |
1990-02-01 |
Merrell Dow Pharmaceut Inc |
抗レトロウィルスジフルオロ化ヌクレオシド類
|
US4987224A
(en)
*
|
1988-08-02 |
1991-01-22 |
University Of Georgia Research Foundation, Inc. |
Method of preparation of 2',3'-dideoxynucleosides
|
US5157114A
(en)
*
|
1988-08-19 |
1992-10-20 |
Burroughs Wellcome Co. |
2',3'-dideoxy-3'-fluoro-5-ethyngluridine
|
US4954623A
(en)
*
|
1989-03-20 |
1990-09-04 |
Eli Lilly And Company |
Recovery of difluoro sugar
|
CA2012129A1
(en)
*
|
1989-03-20 |
1990-09-20 |
Ramakrishnan Nagarajan |
Recovery of difluoro sugar
|
YU43193A
(sh)
*
|
1992-06-22 |
1997-01-08 |
Eli Lilly And Company |
2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
|
HU214030B
(en)
*
|
1992-06-22 |
1997-12-29 |
Lilly Co Eli |
Process for preparing alpha-anomer enriched 1-halogen-2-deoxy-2,2-difluoro-d-ribofuranosyl derivatives
|
US5401861A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5606048A
(en)
*
|
1992-06-22 |
1997-02-25 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5256797A
(en)
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
|
US5252756A
(en)
*
|
1992-06-22 |
1993-10-12 |
Eli Lilly And Company |
Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
|
US5401838A
(en)
*
|
1992-06-22 |
1995-03-28 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5426183A
(en)
*
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5371210A
(en)
*
|
1992-06-22 |
1994-12-06 |
Eli Lilly And Company |
Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
US5821357A
(en)
*
|
1992-06-22 |
1998-10-13 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
|
US5256798A
(en)
*
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5594124A
(en)
*
|
1992-06-22 |
1997-01-14 |
Eli Lilly And Company |
Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
|
NO932286L
(no)
*
|
1992-06-22 |
1993-12-23 |
Lilly Co Eli |
Stereoselektiv anion-glykosyleringsprosess
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US5480992A
(en)
*
|
1993-09-16 |
1996-01-02 |
Eli Lilly And Company |
Anomeric fluororibosyl amines
|
US5428176A
(en)
*
|
1994-04-14 |
1995-06-27 |
Eli Lilly And Company |
Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
|
US5637688A
(en)
*
|
1994-12-13 |
1997-06-10 |
Eli Lilly And Company |
Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
|
US5521294A
(en)
*
|
1995-01-18 |
1996-05-28 |
Eli Lilly And Company |
2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
|
US5559222A
(en)
*
|
1995-02-03 |
1996-09-24 |
Eli Lilly And Company |
Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
|
US5633367A
(en)
|
1995-03-24 |
1997-05-27 |
Eli Lilly And Company |
Process for the preparation of a 2-substituted 3,3-difluorofuran
|
CA2171518A1
(en)
*
|
1995-03-24 |
1996-09-25 |
Douglas Patton Kjell |
Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
|
US5756775A
(en)
*
|
1995-12-13 |
1998-05-26 |
Eli Lilly And Company |
Process to make α,α-difluoro-β-hydroxyl thiol esters
|
EP0779275A2
(en)
|
1995-12-13 |
1997-06-18 |
Eli Lilly And Company |
Alpha, Alpha - Difluoro-beta -hydroxy thiol esters and their synthesis
|
US6001994A
(en)
*
|
1995-12-13 |
1999-12-14 |
Eli Lilly And Company |
Process for making gemcitabine hydrochloride
|
US5808020A
(en)
*
|
1996-08-12 |
1998-09-15 |
Associated Universities, Inc. |
Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
|
US6013790A
(en)
*
|
1996-09-25 |
2000-01-11 |
Board Of Regents University Of Nebraska-Lincoln |
Heavily fluorinated sugar analogs
|
EP0994715A4
(en)
*
|
1997-03-24 |
2001-08-08 |
Lilly Co Eli |
DIFLUORONUCLEOSIDE-PHOSPHONIC ACIDS AND DERIVATIVES THEREOF
|
AU2787199A
(en)
|
1998-02-25 |
1999-09-15 |
Emory University |
2'-fluoronucleosides
|
TW466112B
(en)
*
|
1998-04-14 |
2001-12-01 |
Lilly Co Eli |
Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
|
US6326507B1
(en)
*
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
KR100589032B1
(ko)
*
|
2000-10-20 |
2006-06-14 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
US7435755B2
(en)
*
|
2000-11-28 |
2008-10-14 |
The Trustees Of Dartmouth College |
CDDO-compounds and combination therapies thereof
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
WO2003059334A2
(en)
*
|
2001-10-25 |
2003-07-24 |
Eli Lilly And Company |
Gemcitabine in the treatment of smallpox
|
DK1465615T3
(da)
*
|
2002-01-15 |
2012-11-12 |
Dartmouth College |
Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
|
US20040002476A1
(en)
*
|
2002-02-14 |
2004-01-01 |
Stuyver Lieven J. |
Modified fluorinated nucleoside analogues
|
ATE508747T1
(de)
*
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
AU2003233586A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
US20080026045A1
(en)
*
|
2003-05-20 |
2008-01-31 |
Jonathan Lewis |
Combination Chemotherapy Comprising a Gemcitabine and a Liposomal Platium Complex
|
EP2345658A1
(en)
*
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
US20060034943A1
(en)
*
|
2003-10-31 |
2006-02-16 |
Technology Innovations Llc |
Process for treating a biological organism
|
EP1683785B1
(en)
*
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
CA2554463C
(en)
|
2004-02-06 |
2013-06-11 |
Threshold Pharmaceuticals, Inc. |
Anti-cancer therapies
|
EP1732947B1
(en)
*
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
US20050249667A1
(en)
*
|
2004-03-24 |
2005-11-10 |
Tuszynski Jack A |
Process for treating a biological organism
|
NZ552927A
(en)
*
|
2004-07-21 |
2010-05-28 |
Pharmasset Inc |
Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
KR100578616B1
(ko)
*
|
2004-07-23 |
2006-05-10 |
한미약품 주식회사 |
D-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
|
US7858761B2
(en)
*
|
2004-07-29 |
2010-12-28 |
Hanmi Pharm. Co., Ltd |
1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof
|
TW200606159A
(en)
*
|
2004-07-30 |
2006-02-16 |
Pharmaessentia Corp |
Stereoselective synthesis of β-nucleosides
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
AU2005283422C1
(en)
*
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
US20060089328A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solutions
|
US7563570B2
(en)
*
|
2004-10-29 |
2009-07-21 |
Pangaea Biotech |
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
|
TW200634022A
(en)
*
|
2004-12-08 |
2006-10-01 |
Sicor Inc |
Difluoronucleosides and process for preparation thereof
|
ES2310860T3
(es)
*
|
2004-12-17 |
2009-01-16 |
Eli Lilly And Company |
Profarmaco amida de gemcitabina, composiciones y uso del mismo.
|
CN101146532B
(zh)
|
2005-01-21 |
2012-05-09 |
阿斯泰克斯治疗有限公司 |
药物化合物
|
WO2006092808A1
(en)
*
|
2005-03-04 |
2006-09-08 |
Dabur Pharma Limited |
Intermediate and process for preparing of beta- anomer enriched 21deoxy, 21 ,21-difluoro-d-ribofuranosyl nucleosides
|
US7485716B2
(en)
*
|
2005-05-02 |
2009-02-03 |
Pharmaessentia Corp. |
Stereoselective synthesis of β-nucleosides
|
US7572898B2
(en)
*
|
2005-06-03 |
2009-08-11 |
Scinopharm Taiwan, Ltd. |
Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
|
AU2011202539B2
(en)
*
|
2005-06-03 |
2012-07-05 |
Scinopharm Taiwan, Ltd. |
Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
|
ZA200800907B
(en)
|
2005-07-18 |
2010-04-28 |
Bipar Sciences Inc |
Treatment of cancer
|
AT502221A1
(de)
*
|
2005-07-20 |
2007-02-15 |
Pharmacon Forschung & Beratung Gmbh |
Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
|
WO2007015569A1
(ja)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
WO2007015257A2
(en)
*
|
2005-08-04 |
2007-02-08 |
Hetero Drugs Limited |
A process for the preparation of gemcitabine using novel intermediates
|
EP1938842A4
(en)
*
|
2005-09-01 |
2013-01-09 |
Eisai R&D Man Co Ltd |
METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
|
WO2007049294A1
(en)
|
2005-10-28 |
2007-05-03 |
Arch Pharmalabs Limited |
An improved process for preparation of gemcitabine hydrochloride.
|
AU2006309551B2
(en)
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
EP1964837A4
(en)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumor agent against multiple myeloma
|
BRPI0619928A2
(pt)
*
|
2005-12-14 |
2011-10-25 |
Dong A Pharm Co Ltd |
processo de produção de 2', 2'-difluornucleosìdeo e intermediário
|
WO2007117760A2
(en)
*
|
2006-02-06 |
2007-10-18 |
Dr. Reddy's Laboratories Ltd. |
Preparation of gemcitabine
|
CA2641719A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
US20070249823A1
(en)
*
|
2006-04-20 |
2007-10-25 |
Chemagis Ltd. |
Process for preparing gemcitabine and associated intermediates
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
KR100741310B1
(ko)
*
|
2006-08-01 |
2007-08-01 |
(주) 유일팜테크 |
젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
|
WO2008026748A1
(fr)
*
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US20080161324A1
(en)
*
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
US8299046B2
(en)
*
|
2006-11-17 |
2012-10-30 |
Trustees Of Dartmouth College |
Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
|
US7714012B2
(en)
*
|
2006-11-17 |
2010-05-11 |
Trustees Of Dartmouth University |
Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
|
US8921340B2
(en)
|
2006-11-17 |
2014-12-30 |
Trustees Of Dartmouth College |
Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
|
WO2008088088A1
(ja)
|
2007-01-19 |
2008-07-24 |
Eisai R & D Management Co., Ltd. |
膵癌治療用組成物
|
US8962655B2
(en)
*
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
EP2139884B1
(en)
*
|
2007-03-23 |
2013-12-04 |
Dongwoo Syntech Co., Ltd. |
Process for preparing of 2'-deoxy-2'2'-difluorocytidine
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CN101024667B
(zh)
*
|
2007-03-30 |
2011-01-26 |
湖北益泰药业有限公司 |
盐酸吉西他宾的合成方法
|
WO2008124691A1
(en)
*
|
2007-04-05 |
2008-10-16 |
Threshold Pharmaceuticals, Inc. |
Glufosfamide combination therapy
|
US20080262215A1
(en)
*
|
2007-04-23 |
2008-10-23 |
Chemagis Ltd. |
Gemcitabine production process
|
CN100475832C
(zh)
*
|
2007-05-31 |
2009-04-08 |
南京卡文迪许生物工程技术有限公司 |
一种新颖的高立体选择性合成吉西他滨工艺及中间体
|
EP2202297B1
(en)
*
|
2007-07-18 |
2014-05-14 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
WO2009023845A2
(en)
*
|
2007-08-15 |
2009-02-19 |
The Board Of Regents Of The University Of Texas System |
Combination therapy with synthetic triterpenoids and gemcitabine
|
TWI436775B
(zh)
*
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
US20090069354A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched gemcitabine
|
US8741858B2
(en)
|
2007-09-21 |
2014-06-03 |
Zhongxu Ren |
Oligomer-nucleoside phosphate conjugates
|
JP4253357B1
(ja)
|
2007-09-27 |
2009-04-08 |
株式会社湯山製作所 |
手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
JP2011503093A
(ja)
*
|
2007-11-06 |
2011-01-27 |
ファーマエッセンティア コーポレイション |
β−ヌクレオシドの新規な合成
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
EP2219672B1
(en)
|
2007-11-09 |
2016-02-17 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
MX2010005221A
(es)
*
|
2007-11-12 |
2010-09-28 |
Bipar Sciences Inc |
Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
|
TWI492745B
(zh)
|
2008-01-11 |
2015-07-21 |
Reata Pharmaceuticals Inc |
合成的三萜系化合物及其使用於治療疾病之方法
|
CA2713930A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
JP5529850B2
(ja)
*
|
2008-04-18 |
2014-06-25 |
リアタ ファーマシューティカルズ インコーポレイテッド |
抗酸化炎症モジュレーター:c環中に飽和を有するオレアノール酸誘導体
|
HUE041221T2
(hu)
|
2008-04-18 |
2019-05-28 |
Reata Pharmaceuticals Inc |
Antioxidáns gyulladás modulátorok: a C-17 atomon amino- és más módosításokkal rendelkezõ oleanolsav-származékok
|
TWI584808B
(zh)
|
2008-04-18 |
2017-06-01 |
瑞塔醫藥有限責任公司 |
抗氧化發炎調節劑:c-17同系齊墩果酸衍生物
|
US8258329B2
(en)
*
|
2008-04-18 |
2012-09-04 |
Reata Pharmaceuticals, Inc. |
Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
|
TW201004627A
(en)
*
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
CN102216314A
(zh)
*
|
2008-06-12 |
2011-10-12 |
台湾神隆股份有限公司 |
吉西他滨碱的结晶多晶型物
|
US8314137B2
(en)
*
|
2008-07-22 |
2012-11-20 |
Trustess Of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
WO2010019396A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Threshold Pharmaceuticals, Inc. |
Administration of glufosfamide for the treatment of cancer
|
WO2010049947A2
(en)
*
|
2008-10-28 |
2010-05-06 |
Accrete Pharmaceutical Private Limited |
Preparation of gemcitabine and intermediates thereof
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
PA8855801A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Sintesis de nucleosidos de purina
|
CA2757745C
(en)
*
|
2009-04-06 |
2018-02-13 |
Eisai Inc. |
Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
|
US8609631B2
(en)
|
2009-04-06 |
2013-12-17 |
Eisai Inc. |
Compositions and methods for treating cancer
|
JP5687687B2
(ja)
*
|
2009-04-06 |
2015-03-18 |
大塚製薬株式会社 |
癌を治療するための(2’−デオキシ−リボフラノシル)−1,3,4,7−テトラヒドロ−(1,3)ジアゼピン−2−オン誘導体
|
US8329666B2
(en)
*
|
2009-04-06 |
2012-12-11 |
Eisai Inc. |
Compositions and methods for treating cancer
|
US20100273730A1
(en)
*
|
2009-04-27 |
2010-10-28 |
Innopharmax, Inc. |
Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2011016049A2
(en)
|
2009-07-31 |
2011-02-10 |
Astron Research Limited |
A stable composition of ready-to-use gemcitabine injection
|
WO2011028638A1
(en)
|
2009-09-04 |
2011-03-10 |
Schering Corporation |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
WO2011101644A1
(en)
|
2010-02-18 |
2011-08-25 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Triazolo [4, 5 - b] pyridin derivatives
|
DK2547359T3
(en)
|
2010-03-15 |
2016-06-06 |
The Board Of Trustees Of The Univ Of Illionis |
Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
US8859756B2
(en)
|
2010-03-31 |
2014-10-14 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
WO2011143590A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
|
WO2011143593A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
MX2013003153A
(es)
|
2010-09-22 |
2013-05-01 |
Alios Biopharma Inc |
Analogos de nucleotidos sustituidos.
|
WO2012069972A1
(en)
|
2010-11-19 |
2012-05-31 |
Piramal Life Sciences Limited |
A pharmaceutical combination for the treatment of breast cancer
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
CN102153602B
(zh)
*
|
2011-02-24 |
2013-11-06 |
中国农业大学 |
呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
|
CN102153601A
(zh)
*
|
2011-02-26 |
2011-08-17 |
湖南欧亚生物有限公司 |
一种高选择性的制备盐酸吉西他滨以及其中间体的方法
|
WO2012123889A1
(en)
|
2011-03-14 |
2012-09-20 |
Piramal Healthcare Limited |
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
ES2620644T3
(es)
|
2011-04-01 |
2017-06-29 |
Genentech, Inc. |
Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
|
US8765933B2
(en)
|
2011-04-07 |
2014-07-01 |
Pharmaessentia Corp. |
Asynthesis of β-nucleosides
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
EP2696679B1
(en)
|
2011-04-13 |
2017-08-02 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
PE20140522A1
(es)
|
2011-04-13 |
2014-05-03 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
EP2700403B1
(en)
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
CN102453064B
(zh)
*
|
2011-06-30 |
2014-07-09 |
江苏豪森药业股份有限公司 |
制备吉西他滨盐酸盐的方法
|
EP2731433A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
IN2014DN03485A
(ja)
|
2011-10-03 |
2015-06-05 |
Moreinx Ab |
|
CN102417533A
(zh)
*
|
2011-10-28 |
2012-04-18 |
江苏正大清江制药有限公司 |
盐酸吉西他滨的合成方法
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
NO2755614T3
(ja)
|
2012-01-03 |
2018-03-31 |
|
|
WO2013142124A1
(en)
|
2012-03-21 |
2013-09-26 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
US8921419B2
(en)
|
2012-05-08 |
2014-12-30 |
Trustees Of Dartmouth College |
Triterpenoids and compositions containing the same
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
BR112014028376A2
(pt)
|
2012-06-08 |
2018-04-24 |
Hoffmann La Roche |
métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
|
EP2711008A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
|
EP2711009A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
|
EP2711007A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
|
EA030189B8
(ru)
|
2012-10-08 |
2018-10-31 |
Иденикс Фармасьютикалз Ллс |
Аналоги 2'-хлоронуклеозидов для инфекции вгс
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
WO2014163558A1
(en)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
SG11201509278XA
(en)
|
2013-05-14 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
JP6476591B2
(ja)
*
|
2013-06-05 |
2019-03-06 |
セントラル硝子株式会社 |
(2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類の製造方法
|
WO2015003747A1
(en)
*
|
2013-07-10 |
2015-01-15 |
Asteriapharma Gmbh |
Composition containing modified derivatives of a cytidine antimetabolite for the treatment of susceptible disease
|
CN105792845A
(zh)
*
|
2013-07-26 |
2016-07-20 |
施瑞修德制药公司 |
使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
|
PL3038601T3
(pl)
|
2013-08-27 |
2020-08-24 |
Gilead Pharmasset Llc |
Formulacja złożona dwóch związków przeciwwirusowych
|
ES2712877T3
(es)
|
2013-10-29 |
2019-05-16 |
Otsuka Pharma Co Ltd |
Ruta sintética de 2-desoxi-2,2-difluorotetrahidrouridinas
|
WO2015191563A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination chemotherapy comprising a liposomal prodrug of mitomycin c
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
PL3524595T3
(pl)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Management Co., Ltd. |
Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
WO2016123142A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
US20180044368A1
(en)
*
|
2015-02-25 |
2018-02-15 |
Ligand Pharmaceuticals, Inc. |
Gemcitabine derivatives
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
CN108350016B
(zh)
*
|
2015-09-02 |
2021-07-27 |
艾伯维公司 |
抗病毒四氢呋喃衍生物
|
JP7038653B2
(ja)
*
|
2015-10-05 |
2022-03-18 |
ニューカナ パブリック リミテッド カンパニー |
併用療法
|
AU2016367237B2
(en)
|
2015-12-11 |
2020-12-24 |
Laurus Labs Limited |
Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
|
JP7158023B2
(ja)
|
2016-03-15 |
2022-10-21 |
オリソン ヘノミクス エセ. アー. |
固形腫瘍の治療における使用のための、lsd1阻害剤の組合せ
|
WO2018035046A1
(en)
|
2016-08-15 |
2018-02-22 |
President And Fellows Of Harvard College |
Treating infections using idsd from proteus mirabilis
|
EP3541404A1
(en)
|
2016-11-21 |
2019-09-25 |
Bexion Pharmaceuticals, Inc. |
A combination therapy including sapc-dops for the treatment of pancreatic cancer
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
EP3618837A4
(en)
|
2017-04-26 |
2020-11-04 |
Thomas I. Kalman |
MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
|
MA49849A
(fr)
|
2017-08-07 |
2020-06-17 |
Amgen Inc |
Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
|
SG11202002114RA
(en)
|
2017-09-18 |
2020-04-29 |
Univ California |
Claudin6 antibodies and methods of treating cancer
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
CN112004537A
(zh)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
US11760773B2
(en)
|
2018-02-02 |
2023-09-19 |
Maverix Oncology, Inc. |
Small molecule drug conjugates of gemcitabine monophosphate
|
WO2019178433A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
JP2022517352A
(ja)
|
2019-01-11 |
2022-03-08 |
リポメディックス・ファーマシューティカルズ・リミテッド |
マイトマイシンcのリポソーム化プロドラッグを含むリポソーム組成物および製造法
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
CA3134055A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
EP3962945A1
(en)
|
2019-04-30 |
2022-03-09 |
Instituto de Medicina Molecular João Lobo Antunes |
Rank pathway inhibitors in combination with cdk inhibitors
|
WO2020263793A1
(en)
|
2019-06-24 |
2020-12-30 |
Amgen Inc. |
Inhibition of sirp-gamma for cancer treatment
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
CN115605492A
(zh)
|
2020-04-21 |
2023-01-13 |
配体制药股份有限公司(Us) |
核苷酸前药化合物
|